FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2318261010> ?p ?o ?g. }

• W2318261010 endingPage "36" @default.
• W2318261010 startingPage "30" @default.
• W2318261010 abstract "The effect of formulation parameters on the in vitro release profile of a poorly soluble drug was investigated using rimonabant as model drug. A dissolution test was developed to evaluate the release profile of rimonabant from both 20mg film-coated tablet and capsule dosage forms. The test was applied to compare dissolution profiles of different dosage forms and to evaluate the effect of formulation parameters on the in vitro release profile of the drug. Four different commercially available products were evaluated, and the results obtained show very distinct rates and extent of dissolution among them. The type of excipients used in the capsule formulation significantly influenced the dissolution rate of the formulations studied. INTRODUCTION Many drugs are poorly soluble or insoluble in water, which results in poor bioavailability because the solubility of a drug is an important factor in determining the rate and extent of its absorption (1). Drug release rate is one of the most important parameters for solid oral drug delivery systems; therefore, the therapeutic response is a function of the concentration of drug available to be absorbed and reach the bloodstream (2). Physical factors important to drug dissolution include particle size, molecular size, hydrophilicity, and crystalline structure. The volume of medium into which the drug must dissolve can also play a role in determining the dissolution rate (3). Physical modifications often aim to increase the surface area, solubility, and wettability of the powder particles and, therefore, typically focus on particle size reduction or generation of amorphous states. Classically, particle size reduction is performed by milling, and a wide variety of apparatus is available. The increase in bioavailability after micronization of drugs is well known, and the technique has been applied to a variety of poorly water-soluble compounds (4). Another approach for improving solubility is the complexation and incorporation of drugs into cyclodextrins (5). The incorporation of adjuvants (e.g., diluents, lubricants, and surfactants) into the formulation of a solid oral dosage form can cause significant effects on the dissolution rate of drugs, especially those that are hydrophobic and poorly soluble (6). In the case of Class 2 drugs in the Biopharmaceutics Classification System (BCS), dissolution may be the ratelimiting step for drug absorption, so suitable dissolution tests can be used to predict differences in bioavailability among different formulations (7). The choice of formulation is often of critical importance in establishing a successful product for oral administration of this class of drugs (8). In this context, the purpose of the present study was to evaluate and compare the dissolution profiles of several compounded formulations to that of a reference product using rimonabant as a model drug. This drug is poorly soluble in water and has high in vitro permeability; it is therefore classified as BCS Class 2 (9). To date, there is no published dissolution test for the evaluation of in vitro release profiles of this drug from immediate-release solid oral dosage forms. Therefore, we also developed a dissolution method for rimonabant to determine its release profiles from pharmaceutical formulations. We prepared several formulations containing different types and proportions of excipients and variations in drug particle size to assess the influence of formulation and drug physical properties on the dissolution kinetics of the drug MATERIALS AND METHODS Chemicals Rimonabant reference substance (99.5%) was purchased from Sequoia Research Products (Pangbourne, UK). Acomplia (Sanofi–Aventis, Paris, France) film-coated tablets and compounded capsules containing 20 mg of rimonabant were obtained from commercial sources. Gradient grade LiChrosolv acetonitrile and methanol were *Corresponding author. Current address: Departamento de Farmacia Industrial, Universidade Federal de Santa Maria, Av. Roraima 1000, 97105900 Santa Maria, RS, Brazil. e-mail: crolim@smail.ufsm.br dx.doi.org/10.14227/DT190312P30" @default.
• W2318261010 created "2016-06-24" @default.
• W2318261010 creator A5001329248 @default.
• W2318261010 creator A5022756267 @default.
• W2318261010 creator A5031878942 @default.
• W2318261010 creator A5034604154 @default.
• W2318261010 creator A5044697791 @default.
• W2318261010 creator A5071062777 @default.
• W2318261010 date "2012-01-01" @default.
• W2318261010 modified "2023-09-27" @default.
• W2318261010 title "Development of a Discriminating In Vitro Dissolution Method for the Poorly Soluble Drug Rimonabant: Effect of Formulation Variables on Dosage Form Release Profiles" @default.
• W2318261010 cites W1555994455 @default.
• W2318261010 cites W1587951740 @default.
• W2318261010 cites W1968706872 @default.
• W2318261010 cites W1997764055 @default.
• W2318261010 cites W2011707100 @default.
• W2318261010 cites W2012626597 @default.
• W2318261010 cites W2021318457 @default.
• W2318261010 cites W2041650702 @default.
• W2318261010 cites W2044256946 @default.
• W2318261010 cites W2048013288 @default.
• W2318261010 cites W2049599102 @default.
• W2318261010 cites W2056995570 @default.
• W2318261010 cites W2061263372 @default.
• W2318261010 cites W2065769066 @default.
• W2318261010 cites W2070825233 @default.
• W2318261010 cites W2073390911 @default.
• W2318261010 cites W2314350868 @default.
• W2318261010 cites W2415382320 @default.
• W2318261010 cites W97938539 @default.
• W2318261010 doi "https://doi.org/10.14227/dt190312p30" @default.
• W2318261010 hasPublicationYear "2012" @default.
• W2318261010 type Work @default.
• W2318261010 sameAs 2318261010 @default.
• W2318261010 citedByCount "3" @default.
• W2318261010 countsByYear W23182610102014 @default.
• W2318261010 countsByYear W23182610102017 @default.
• W2318261010 crossrefType "journal-article" @default.
• W2318261010 hasAuthorship W2318261010A5001329248 @default.
• W2318261010 hasAuthorship W2318261010A5022756267 @default.
• W2318261010 hasAuthorship W2318261010A5031878942 @default.
• W2318261010 hasAuthorship W2318261010A5034604154 @default.
• W2318261010 hasAuthorship W2318261010A5044697791 @default.
• W2318261010 hasAuthorship W2318261010A5071062777 @default.
• W2318261010 hasBestOaLocation W23182610101 @default.
• W2318261010 hasConcept C148001335 @default.
• W2318261010 hasConcept C170493617 @default.
• W2318261010 hasConcept C178790620 @default.
• W2318261010 hasConcept C185592680 @default.
• W2318261010 hasConcept C202751555 @default.
• W2318261010 hasConcept C2776433454 @default.
• W2318261010 hasConcept C2776885963 @default.
• W2318261010 hasConcept C2780035454 @default.
• W2318261010 hasConcept C3019981671 @default.
• W2318261010 hasConcept C43617362 @default.
• W2318261010 hasConcept C55493867 @default.
• W2318261010 hasConcept C71924100 @default.
• W2318261010 hasConcept C77281830 @default.
• W2318261010 hasConcept C88380143 @default.
• W2318261010 hasConcept C98274493 @default.
• W2318261010 hasConceptScore W2318261010C148001335 @default.
• W2318261010 hasConceptScore W2318261010C170493617 @default.
• W2318261010 hasConceptScore W2318261010C178790620 @default.
• W2318261010 hasConceptScore W2318261010C185592680 @default.
• W2318261010 hasConceptScore W2318261010C202751555 @default.
• W2318261010 hasConceptScore W2318261010C2776433454 @default.
• W2318261010 hasConceptScore W2318261010C2776885963 @default.
• W2318261010 hasConceptScore W2318261010C2780035454 @default.
• W2318261010 hasConceptScore W2318261010C3019981671 @default.
• W2318261010 hasConceptScore W2318261010C43617362 @default.
• W2318261010 hasConceptScore W2318261010C55493867 @default.
• W2318261010 hasConceptScore W2318261010C71924100 @default.
• W2318261010 hasConceptScore W2318261010C77281830 @default.
• W2318261010 hasConceptScore W2318261010C88380143 @default.
• W2318261010 hasConceptScore W2318261010C98274493 @default.
• W2318261010 hasIssue "3" @default.
• W2318261010 hasLocation W23182610101 @default.
• W2318261010 hasOpenAccess W2318261010 @default.
• W2318261010 hasPrimaryLocation W23182610101 @default.
• W2318261010 hasRelatedWork W1571130805 @default.
• W2318261010 hasRelatedWork W1977764645 @default.
• W2318261010 hasRelatedWork W2054827224 @default.
• W2318261010 hasRelatedWork W2083745571 @default.
• W2318261010 hasRelatedWork W2410175939 @default.
• W2318261010 hasRelatedWork W2460492823 @default.
• W2318261010 hasRelatedWork W2549910096 @default.
• W2318261010 hasRelatedWork W2791912237 @default.
• W2318261010 hasRelatedWork W2883365895 @default.
• W2318261010 hasRelatedWork W2337440106 @default.
• W2318261010 hasVolume "19" @default.
• W2318261010 isParatext "false" @default.
• W2318261010 isRetracted "false" @default.
• W2318261010 magId "2318261010" @default.
• W2318261010 workType "article" @default.